Data / Drug companies / Sandoz Inc
Sandoz Inc: 327 products in the FDA NDC directory, labeler code 0781
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sandoz Inc (labeler code 0781) lists 327 products in the FDA National Drug Code Directory, covering 115 finished drugs by generic name. By type: 323 prescription drugs, 3 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 12, 2026.
The request: Watch Sandoz Inc (FDA labeler code 0781): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0781
- Products in commercial distribution
- 327
- Packages
- 464
- Finished drugs by generic name
- 115
- Prescription products
- 323
- Over the counter products
- 3
- Controlled substance products
- Schedule II 29, Schedule III 1, Schedule IV 12
- Flagged as original packager
- 291 of 291 products that carry the flag
- Started marketing in the last 12 months
- 35
- Products with a marketing end date set
- 22
- Earliest marketing start
- March 3, 1971
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 254 | 77.7% |
| Authorized generics (NDA) | 59 | 18% |
| New drug applications (NDA) | 10 | 3.1% |
| Biologics (BLA) | 3 | 0.9% |
| Drugs for further processing | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 323 | 98.8% |
| Over the counter drugs | 3 | 0.9% |
| Drugs for further processing | 1 | 0.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 48 | 14.7% |
| Injection, solution | 47 | 14.4% |
| Injection | 43 | 13.1% |
| Injection, powder, for solution | 37 | 11.3% |
| Capsule | 28 | 8.6% |
| Capsule, extended release | 24 | 7.3% |
| Tablet | 21 | 6.4% |
| Injection, powder, lyophilized, for solution | 12 | 3.7% |
| Patch, extended release | 8 | 2.4% |
| Kit | 7 | 2.1% |
| Powder, for suspension | 6 | 1.8% |
| Patch | 6 | 1.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lidocaine hydrochloride | 0781-3539 | Injection, solution | Generic drugs (ANDA) | October 12, 2026 |
| Lidocaine hydrochloride | 0781-3537 | Injection, solution | Generic drugs (ANDA) | October 12, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2734 | Capsule, extended release | Authorized generics (NDA) | October 1, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2733 | Capsule, extended release | Authorized generics (NDA) | October 1, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2732 | Capsule, extended release | Authorized generics (NDA) | October 1, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2731 | Capsule, extended release | Authorized generics (NDA) | October 1, 2026 |
| Bumetanide | 0781-8160 | Tablet | Generic drugs (ANDA) | September 28, 2026 |
| Bumetanide | 0781-8113 | Tablet | Generic drugs (ANDA) | September 28, 2026 |
| Bumetanide | 0781-8099 | Tablet | Generic drugs (ANDA) | September 28, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2730 | Capsule, extended release | Authorized generics (NDA) | September 24, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2729 | Capsule, extended release | Authorized generics (NDA) | September 24, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2728 | Capsule, extended release | Authorized generics (NDA) | September 24, 2026 |
| Dexmethylphenidate Hydrochloride Extended-Release | 0781-2727 | Capsule, extended release | Authorized generics (NDA) | September 24, 2026 |
| Pomalidomide | 0781-2369 | Capsule | Generic drugs (ANDA) | September 1, 2026 |
| Pomalidomide | 0781-2366 | Capsule | Generic drugs (ANDA) | September 1, 2026 |
| Pomalidomide | 0781-2358 | Capsule | Generic drugs (ANDA) | September 1, 2026 |
| Pomalidomide | 0781-2354 | Capsule | Generic drugs (ANDA) | September 1, 2026 |
| Fidaxomicin | 0781-5194 | Tablet, film coated | Generic drugs (ANDA) | August 27, 2026 |
| Sugammadex | 0781-3469 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex | 0781-3468 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Mesalamine | 0781-2791 | Capsule, extended release | Generic drugs (ANDA) | July 21, 2026 |
| Mesalamine | 0781-2793 | Capsule, extended release | Generic drugs (ANDA) | July 15, 2026 |
| Ferric Carboxymaltose | 0781-3542 | Injection, solution | Authorized generics (NDA) | July 3, 2026 |
| Sitagliptin and Metformin Hydrochloride | 0781-5802 | Tablet, film coated | Generic drugs (ANDA) | May 28, 2026 |
| Sitagliptin and Metformin Hydrochloride | 0781-5801 | Tablet, film coated | Generic drugs (ANDA) | May 28, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.